Novo Nordisk : EMA's CHMP Backs Ozempic Label Update

Novo Nordisk (NVO) has received a positive opinion from the European Medicines Agency's CHMP to update Ozempic's label, incorporating functional outcomes data from the STRIDE trial for peripheral artery disease, with European Commission implementation expected within two months. The company has also filed for a U.S. label expansion for Ozempic, with a decision anticipated in Q4 2025. Additionally, Novo Nordisk has sought label expansion for Rybelsus with both the EMA and FDA, potentially positioning it as the first oral GLP-1 RA with proven cardiovascular benefits, with decisions expected in the second half of 2025. This regulatory momentum expands the market potential and strengthens the cardiovascular indication for Novo Nordisk's key GLP-1 assets.

Analysis

Novo Nordisk has secured a significant regulatory victory with a positive opinion from the EMA's CHMP to expand the label for its key drug, Ozempic. This update, based on the STRIDE trial, will incorporate data on functional outcomes in peripheral artery disease (PAD), a new therapeutic area that widens the drug's addressable market in Europe. The final European Commission decision is expected within approximately two months, representing a near-term catalyst. This European progress is complemented by a longer-term strategy in the U.S., where a similar label expansion for Ozempic has been filed, with a regulatory decision anticipated in the fourth quarter of 2025. Furthermore, Novo Nordisk is reinforcing its GLP-1 franchise by seeking label expansions for Rybelsus with both the EMA and FDA. If approved in the second half of 2025, Rybelsus could become the first oral GLP-1 with a proven cardiovascular benefit, creating a substantial competitive advantage and potentially accelerating market share capture in the oral treatment segment.

Key Decisions for Investors

• Investors should view the imminent European label update for Ozempic as a near-term positive catalyst that reinforces Novo Nordisk's revenue growth outlook.
• The multiple label expansion filings for both Ozempic and Rybelsus through 2025 signal a robust pipeline of value-unlocking events that could further solidify the company's dominance in the GLP-1 market.
• The potential for Rybelsus to be the first oral GLP-1 with a cardiovascular benefit indication is a key differentiator to monitor, as it could significantly expand its patient base and competitive moat.